City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, and Adagene Inc., a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the launch of an innovative Phase 1 clinical trial to explore a new combination therapy for patients battling metastatic colorectal cancer, particularly for those whose disease has resisted standard treatments.